Theme Settings
Color Scheme
Light
Dark
Layout Mode
Fluid
Boxed
Topbar Color
Light
Dark
Brand

Gene Differential Expression with Hotspot Mutation

In this panel, you can compare gene/signature expression level between patients with and without key hotspot mutations.

GEPIA performs ANOVA or Wilcoxon rank-sum test for differential expression analysis with hotspot mutation. Only significant results will be provided (p < 0.1). Meanwhile, you can compare expression correlation between your query gene and hotspot gene in mutant or non-mutant cases by click 'plot' button. Spearman's r was used in Correlation analysis. Only primary tumor expression level was included in this function. The criteria for hotspot mutations are mutation frequency > 0.05 and occurrence in at least 10 samples.

Parameters:

  • Gene: Input a gene/isoform or gene signature A of interest.
  • Methods: Select ANOVA or Wilcoxon for differential analysis.
  • log2 transformed: Select whether use log2(TPM+1) as expression abundance.
  • Hotspot Mutation Type: Select the type of mutation. Gene level means any nonsilent mutation in the gene. Amino acid level means changes at specific amino acid site (HGSV protein-level).
  • Datasets Selection: Select one or multiple cancer types of interest in the "Dataset Selection" field and click "add" to build dataset list in the "Datasets" field.
  • Plot Color: Choose group color to plot differential expression boxplot and correlation scatter plot.

Results:

  • The table shows the significant results of differential expression between hotspot mutant and wildtype cases. Click the button beside mutation to plot gene/signature expression distribution of mutant and wildtype groups, as well as the expression correlation with the hotspot gene.

Note: always use log-scale axis for visualization, regardless of whether calculated on log-scale.

Tips: Ctrl/Command + A: select all cancer types

TCGA Abbr.
Abbr Detail
ACC Adrenocortical carcinoma
BLCA Bladder Urothelial Carcinoma
BRCA Breast invasive carcinoma
CESC Cervical squamous cell carcinoma and endocervical adenocarcinoma
CHOL Cholangiocarcinoma
COAD Colon adenocarcinoma
DLBC Lymphoid Neoplasm Diffuse Large B-cell Lymphoma
ESCA Esophageal carcinoma
GBM Glioblastoma multiforme
HNSC Head and Neck squamous cell carcinoma
KICH Kidney Chromophobe
KIRC Kidney renal clear cell carcinoma
KIRP Kidney renal papillary cell carcinoma
LAML Acute Myeloid Leukemia
LGG Brain Lower Grade Glioma
LIHC Liver hepatocellular carcinoma
LUAD Lung adenocarcinoma
LUSC Lung squamous cell carcinoma
MESO Mesothelioma
OV Ovarian serous cystadenocarcinoma
PAAD Pancreatic adenocarcinoma
PCPG Pheochromocytoma and Paraganglioma
PRAD Prostate adenocarcinoma
READ Rectum adenocarcinoma
SARC Sarcoma
SKCM Skin Cutaneous Melanoma
STAD Stomach adenocarcinoma
TGCT Testicular Germ Cell Tumors
THCA Thyroid carcinoma
THYM Thymoma
UCEC Uterine Corpus Endometrial Carcinoma
UCS Uterine Carcinosarcoma
UVM Uveal Melanoma
TCGA Abbr.
Abbr Detail
ACC Adrenocortical carcinoma
BLCA Bladder Urothelial Carcinoma
BRCA Breast invasive carcinoma
CESC Cervical squamous cell carcinoma and endocervical adenocarcinoma
CHOL Cholangiocarcinoma
COAD Colon adenocarcinoma
DLBC Lymphoid Neoplasm Diffuse Large B-cell Lymphoma
ESCA Esophageal carcinoma
GBM Glioblastoma multiforme
HNSC Head and Neck squamous cell carcinoma
KICH Kidney Chromophobe
KIRC Kidney renal clear cell carcinoma
KIRP Kidney renal papillary cell carcinoma
LAML Acute Myeloid Leukemia
LGG Brain Lower Grade Glioma
LIHC Liver hepatocellular carcinoma
LUAD Lung adenocarcinoma
LUSC Lung squamous cell carcinoma
MESO Mesothelioma
OV Ovarian serous cystadenocarcinoma
PAAD Pancreatic adenocarcinoma
PCPG Pheochromocytoma and Paraganglioma
PRAD Prostate adenocarcinoma
READ Rectum adenocarcinoma
SARC Sarcoma
SKCM Skin Cutaneous Melanoma
STAD Stomach adenocarcinoma
TGCT Testicular Germ Cell Tumors
THCA Thyroid carcinoma
THYM Thymoma
UCEC Uterine Corpus Endometrial Carcinoma
UCS Uterine Carcinosarcoma
UVM Uveal Melanoma

License Statement: All content on this website is freely available to all users, including for commercial use.